12/15/2020 6:09:33 AM
Allogene Therapeutics And Overland Form JV To Develop And Commercialize AlloCAR T Cell Therapies
7/20/2020 8:33:00 AM
Notch Therapeutics Appoints David Main As President And CEO
6/1/2020 10:09:14 PM
Allogene Therapeutics Prices Public Offering Of 11.70 Mln Shares At $47.00/shr
6/1/2020 6:42:10 AM
Allogene Therapeutics Announces Commencement Of Public Offering Of $450.0 Mln Of Common Stock
3/24/2020 7:08:35 AM
MaxCyte, Allogene Therapeutics Sign Clinical And Commercial License Deal To Enable Advancement Of AlloCAR T Therapies
8/7/2019 7:53:53 AM
Allogene Therapeutics Q2 Net Loss $41.2 Mln Or $0.41/Shr Vs Loss Of $134.9 Mln Or $43.82/Shr Last Year
1/17/2019 12:37:40 PM
PayPal Appoints Deborah Messemer To Its Board Of Directors
12/3/2018 7:56:02 PM
Allogene, Servier Present Data From Phase 1 Trials Of Allogeneic UCART19 In Relapsed/RAL Leukemia